{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T12:18:29Z","timestamp":1778156309887,"version":"3.51.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Chongqing medical scientific research project","award":["2026KFXM067"],"award-info":[{"award-number":["2026KFXM067"]}]},{"name":"the Chongqing medical scientific research project","award":["2024QNXM050"],"award-info":[{"award-number":["2024QNXM050"]}]},{"name":"the Chongqing medical scientific research project","award":["2024MSXM117"],"award-info":[{"award-number":["2024MSXM117"]}]},{"name":"the Chongqing medical scientific research project","award":["2024MSXM153"],"award-info":[{"award-number":["2024MSXM153"]}]},{"name":"the Chongqing medical scientific research project","award":["2026DBXM001"],"award-info":[{"award-number":["2026DBXM001"]}]},{"name":"Medical Youth Top-Talent Project in Chongqing","award":["YXQN202580"],"award-info":[{"award-number":["YXQN202580"]}]},{"name":"the Prevention\u00a0and\u00a0Control\u00a0of\u00a0Emerging\u00a0and\u00a0Major\u00a0Infectious\u00a0Diseases-National\u00a0Science\u00a0and\u00a0 Technology\u00a0Major\u00a0Project","award":["2025ZD01904904"],"award-info":[{"award-number":["2025ZD01904904"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-12987-3","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T03:04:11Z","timestamp":1774667051000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Albuvirtide plus 3BNC117 provides a promising combination strategy for multidrug-resistant HIV-1 infection: a prospective, open-label, multicenter phase 2 trial"],"prefix":"10.1186","volume":"26","author":[{"given":"Yihong","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingxia","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay","family":"Harypursat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaokai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,28]]},"reference":[{"key":"12987_CR1","volume-title":"HIV drug resistance: brief report 2024","author":"WHO","year":"2024","unstructured":"WHO. HIV drug resistance: brief report 2024. Geneva: World Health Organization; 2024. https:\/\/iris.who.int\/bitstream\/handle\/10665\/376039\/9789240086319-eng.pdf.Cit\u00e9. 24 oct 2024. Disponible sur."},{"key":"12987_CR2","volume-title":"Global action plan on HIV drug resistance 2017\u20132021","author":"WHO","year":"2017","unstructured":"WHO. Global action plan on HIV drug resistance 2017\u20132021. Geneva: World Health Organization; 2017. Cit\u00e9 24 oct 2024. https:\/\/iris.who.int\/bitstream\/handle\/10665\/255883\/9789241512848-eng.pdf."},{"key":"12987_CR3","doi-asserted-by":"crossref","unstructured":"Thavarajah JJ, Honge BL, Wejse CM. The Use of broadly neutralizing antibodies (bNAbs) in HIV-1 Treatment and prevention. Viruses. 2024; 16(6):911.","DOI":"10.3390\/v16060911"},{"issue":"11","key":"12987_CR4","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1038\/s41591-022-02023-7","volume":"28","author":"JD Gunst","year":"2022","unstructured":"Gunst JD, Pahus MH, Rosas-Umbert M, Lu IN, Benfield T, Nielsen H, et al. Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b\/2a randomized trial. Nat Med. 2022;28(11):2424\u201335.","journal-title":"Nat Med"},{"issue":"24","key":"12987_CR5","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1097\/CM9.0000000000001273","volume":"133","author":"B SSu","year":"2020","unstructured":"SSu B, Yao C, Zhao QX, Cai WP, Wang M, Lu HZ, et al. Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with HIV-1: interim analysis of the randomized controlled phase 3 non-inferiority TALENT study. Chin Med J (Engl). 2020;133(24):2919\u201327.","journal-title":"Chin Med J (Engl)"},{"issue":"3","key":"12987_CR6","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jinf.2022.05.034","volume":"85","author":"B Su","year":"2022","unstructured":"Su B, Yao C, Zhao QX, Cai WP, Wang M, Lu HZ, et al. Long-acting HIV fusion inhibitor albuvirtide combined with ritonavir-boosted lopinavir after failure of first-line ART: 48-week randomized controlled phase 3 non-inferiority TALENT study. J Infect. 2022;85(3):334\u201363.","journal-title":"J Infect"},{"issue":"7","key":"12987_CR7","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.3390\/molecules26071964","volume":"26","author":"X Wang","year":"2021","unstructured":"Wang X, Cao M, Wu Y, Xu W, Wang Q, Ying T, et al. Synergistic effect of combining a gp120-binding protein and a gp41-binding antibody to inactivate HIV-1 virions and inhibit infection. Molecules. 2021;26(7):1996.","journal-title":"Molecules"},{"key":"12987_CR8","doi-asserted-by":"publisher","first-page":"734110","DOI":"10.3389\/fimmu.2021.734110","volume":"12","author":"RT van Dorsten","year":"2021","unstructured":"van Dorsten RT, Wagh K, Moore PL, Morris L. Combinations of single-chain variable fragments from HIV broadly neutralizing antibodies demonstrate high potency and breadth. Front Immunol. 2021;12:734110.","journal-title":"Front Immunol"},{"issue":"3","key":"12987_CR9","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.1016\/S2352-3018(23)00293-X","volume":"11","author":"JJ Eron","year":"2024","unstructured":"Eron JJ, Little SJ, Crofoot G, Cook P, Ruane PJ, Jayaweera D, et al. Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b randomized proof-of-concept study. Lancet HIV. 2024;11(3):e146\u201355.","journal-title":"Lancet HIV"},{"key":"12987_CR10","unstructured":"National Health Commission Disease Control and Prevention Bureau. Report on the Nutrition and Chronic Disease Status of Chinese Residents. (2020). Beijing: People\u2019s Medical Publishing House. (2021). p. 113."},{"issue":"7724","key":"12987_CR11","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41586-018-0531-2","volume":"561","author":"P Mendoza","year":"2018","unstructured":"Mendoza P, Gruell H, Nogueira L, Pai JA, Butler AL, Millard K, et al. Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature. 2018;561(7724):479\u201384.","journal-title":"Nature"},{"key":"12987_CR12","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12981-016-0091-1","volume":"13","author":"H Zhang","year":"2016","unstructured":"Zhang H, Jin R, Yao C, Zhang T, Wang M, Xia W, et al. Combination of long-acting HIV fusion inhibitor albuvirtide and LPV\/r shows potent efficacy in HIV-1 patients. AIDS Res Ther. 2016;13:8.","journal-title":"AIDS Res Ther"},{"issue":"8","key":"12987_CR13","doi-asserted-by":"publisher","first-page":"e0219142","DOI":"10.1371\/journal.pone.0219142","volume":"14","author":"YZ Cohen","year":"2019","unstructured":"Cohen YZ, Butler AL, Millard K, Witmer-Pack M, Levin R, Unson-O\u2019Brien C, et al. Safety, pharmacokinetics, and immunogenicity of the combination of broadly neutralizing antibodies 3BNC117 and 10-1074 in healthy adults: a randomized phase 1 study. PLoS ONE. 2019;14(8):e0219142.","journal-title":"PLoS ONE"},{"issue":"7913","key":"12987_CR14","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/s41586-022-04597-1","volume":"606","author":"C Gaebler","year":"2022","unstructured":"Gaebler C, Nogueira L, Stoffel E, Oliveira TY, Breton G, Millard KG, et al. Prolonged viral suppression with anti-HIV-1 antibody therapy. Nature. 2022;606(7913):368\u201374.","journal-title":"Nature"},{"key":"12987_CR15","doi-asserted-by":"publisher","first-page":"108163","DOI":"10.1016\/j.ijid.2025.108163","volume":"162","author":"Y Fu","year":"2026","unstructured":"Fu Y, Xie X, Gan L, Yang X, Song Y, Song C, et al. Safety, pharmacokinetics, and efficacy of albuvirtide administered every 4 weeks with dolutegravir in virologically suppressed adults with HIV: a 24-week study. Int J Infect Dis. 2026;162:108163.","journal-title":"Int J Infect Dis"},{"issue":"7","key":"12987_CR16","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1097\/QAD.0000000000004130","volume":"39","author":"X Xie","year":"2025","unstructured":"Xie X, Fu Y, Gan L, Yang X, Song Y, Song C, et al. Safety and efficacy of switching to 4-weekly albuvirtide plus daily dolutegravir in virologically suppressed adults with HIV-1: a 24-week study. AIDS. 2025;39(7):857\u201362.","journal-title":"AIDS"},{"issue":"2","key":"12987_CR17","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1159\/000331998","volume":"55","author":"MW Tang","year":"2012","unstructured":"Tang MW, Liu TF, Shafer RW. The HIVdb system for HIV-1 genotypic resistance interpretation. Intervirology. 2012;55(2):98\u2013101.","journal-title":"Intervirology"},{"issue":"13","key":"12987_CR18","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1056\/NEJMoa1902493","volume":"382","author":"M Kozal","year":"2020","unstructured":"Kozal M, Aberg J, Pialoux G, Cahn P, Thompson M, Molina JM, et al. Fostemsavir in adults with multidrug-resistant HIV-1 infection. N Engl J Med. 2020;382(13):1232\u201343.","journal-title":"N Engl J Med"},{"issue":"2","key":"12987_CR19","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/QAI.0000000000003648","volume":"99","author":"JC Gathe","year":"2025","unstructured":"Gathe JC, DeJesus E, Ramgopal MN, Rolle CP, Yang OO, Sanchez WE, et al. Leronlimab treatment for multidrug-resistant HIV-1 (OPTIMIZE): a randomized double-blind placebo-controlled trial. J Acquir Immune Defic Syndr. 2025;99(2):185\u201394.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"7","key":"12987_CR20","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJMoa1711460","volume":"379","author":"B Emu","year":"2018","unstructured":"Emu B, Fessel J, Schrader S, Kumar P, Richmond G, Win S, et al. Phase 3 study of ibalizumab for multidrug-resistant HIV-1. N Engl J Med. 2018;379(7):645\u201354.","journal-title":"N Engl J Med"},{"issue":"19","key":"12987_CR21","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1056\/NEJMoa2115542","volume":"386","author":"S Segal-Maurer","year":"2022","unstructured":"Segal-Maurer S, DeJesus E, Stellbrink HJ, Castagna A, Richmond GJ, Sinclair GI, et al. Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection. N Engl J Med. 2022;386(19):1793\u2013803.","journal-title":"N Engl J Med"},{"key":"12987_CR22","doi-asserted-by":"publisher","first-page":"1397743","DOI":"10.3389\/fcimb.2024.1397743","volume":"14","author":"L Fan","year":"2024","unstructured":"Fan L, Hu Y, Li R, Ding J, Liu Y, Yu S, et al. Enhanced immune reconstitution with albuvirtide in HIV-infected immunological non-responders. Front Cell Infect Microbiol. 2024;14:1397743.","journal-title":"Front Cell Infect Microbiol"},{"issue":"7","key":"12987_CR23","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1097\/DCR.0000000000002009","volume":"64","author":"CB Sanger","year":"2021","unstructured":"Sanger CB, Xu Y, Carchman E, Lawson EH, Heise CP, Striker R, et al. Prevalence of high-grade anal dysplasia and anal cancer in veterans living with HIV and CD4\/CD8 ratio as a marker for increased risk. Dis Colon Rectum. 2021;64(7):805\u201311.","journal-title":"Dis Colon Rectum"},{"issue":"2","key":"12987_CR24","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1016\/S2352-3018(16)30215-6","volume":"4","author":"K Sigel","year":"2017","unstructured":"Sigel K, Wisnivesky J, Crothers K, Gordon K, Brown ST, Rimland D, et al. Immunological and infectious risk factors for lung cancer in US veterans with HIV: a longitudinal cohort study. Lancet HIV. 2017;4(2):e67\u201373.","journal-title":"Lancet HIV"},{"issue":"6","key":"12987_CR25","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1093\/jnci\/djac053","volume":"114","author":"JL Castilho","year":"2022","unstructured":"Castilho JL, Bian A, Jenkins CA, Shepherd BE, Sigel K, Gill MJ, et al. CD4\/CD8 ratio and cancer risk among adults with HIV. J Natl Cancer Inst. 2022;114(6):854\u201362.","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"12987_CR26","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1097\/QAD.0000000000001005","volume":"30","author":"JL Castilho","year":"2016","unstructured":"Castilho JL, Shepherd BE, Koethe J, Turner M, Bebawy S, Logan J, et al. CD4+\/CD8\u2009+\u2009ratio, age, and risk of serious noncommunicable diseases in adults with HIV on ART. AIDS. 2016;30(6):899\u2013908.","journal-title":"AIDS"},{"issue":"9","key":"12987_CR27","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1093\/cid\/ciad136","volume":"76","author":"R Ron","year":"2023","unstructured":"Ron R, Moreno E, Martinez-Sanz J, Branas F, Sainz T, Moreno S, et al. CD4\/CD8 ratio during HIV treatment: time for routine monitoring? Clin Infect Dis. 2023;76(9):1688\u201396.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"12987_CR28","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1097\/QAD.0000000000003575","volume":"37","author":"P Tebas","year":"2023","unstructured":"Tebas P, Lynn K, Azzoni L, Cocchella G, Papasavvas E, Fair M, et al. Susceptibility to 3BNC117 and 10-1074 in ART-suppressed chronically infected persons. AIDS. 2023;37(8):1203\u20137.","journal-title":"AIDS"},{"key":"12987_CR29","doi-asserted-by":"publisher","first-page":"105151","DOI":"10.1016\/j.ebiom.2024.105151","volume":"104","author":"MA Rai","year":"2024","unstructured":"Rai MA, Blazkova J, Justement JS, Shi V, Kennedy BD, Manning MR, et al. Ex vivo sensitivity to broadly neutralizing antibodies and anti-CD4 antibody UB-421 in multidrug-resistant HIV. EBioMedicine. 2024;104:105151.","journal-title":"EBioMedicine"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-12987-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12987-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12987-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T12:03:31Z","timestamp":1778155411000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-12987-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,28]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["12987"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-12987-3","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,28]]},"assertion":[{"value":"11 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the institutional review boards of all participating centers in China: Chongqing Public Health Medical Center (2020-078-01), The Sixth People\u2019s Hospital of Zhengzhou (IEC-2021-016-01), and First Hospital of Changsha (20210203CSSY00102). The study was also approved by the Advarra Institutional Review Board, USA (IRB #: Pro00044499). All procedures involving human participants were conducted in accordance with the ethical standards of the relevant institutional and\/or national research committees and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Written informed consent was obtained from all participants prior to enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"In accordance with the journal\u2019s policy on competing interests, the authors disclose the following: DX is an employee of Frontier Biotechnologies Inc. and receives research funding from the company. XL receives salary support from Frontier Biotechnologies Inc. All authors have unrestricted access to the study data and analyses and have approved the final version of the manuscript. All other authors have declared that no competing interests exist. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"911"}}